Physician profile
Ajoy Kumar
NPI 1528267457
$1,453.49
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $301 · 2023: $20.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $298.52 | 2019-2020 | |
| Novo Nordisk INC | $166.86 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $156.56 | 2019 | |
| Sunovion Pharmaceuticals INC. | $146.92 | 2019-2020 | |
| Genentech USA, INC. | $141.17 | 2019 | |
| Merck Sharp & Dohme LLC | $93.45 | 2019-2023 | Dificid |
| Glaxosmithkline, LLC. | $83.05 | 2019-2020 | |
| Astellas Pharma US INC | $71.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.49 | 2019-2020 | |
| Amarin Pharma, INC. | $35.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.52 | 2019 | |
| Allergan, INC. | $23.60 | 2019 | |
| Smith+Nephew, INC. | $21.88 | 2019 | |
| Portola Pharmaceuticals, LLC | $20.32 | 2020 | |
| Abbvie INC. | $19.40 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $16.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.90 | 2019 | |
| Amgen INC. | $14.01 | 2019 | |
| Ucb, INC. | $13.17 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.77 | 2019 | |
| Insmed, INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajoy Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.